October Pharma results, Q4 2023
Net profit, assets, equity and cash flow for Q4 2023, against the same period a year earlier, from the published financial statements.
Net profit51.39 millionEGP · +134.8% vs the same period a year earlier
Total assets1.14 billionEGP · +19.8% vs the same period a year earlier
Shareholders' equity590 millionEGP · +38.5% vs the same period a year earlier
Operating cash flow61.37 millionEGP · +504.3% vs the same period a year earlier
In short
- October Pharma's net profit for Q4 2023 was about 51.39 million EGP, up +134.8% from 21.88 million EGP in Q4 2022.
- Total assets at the end of Q4 2023 were about 1.14 billion EGP, and shareholders' equity about 590 million EGP.
- Operating cash flow for Q4 2023 was positive at 61.37 million EGP.
Key lines against the same period a year earlier
This periodQ4 2022Change
Net profit51.39 million21.88 million+134.8%
Gross profit144 million95.99 million+50.2%
Total assets1.14 billion950 million+19.8%
Total liabilities549 million524 million+4.6%
Shareholders' equity590 million426 million+38.5%
Total liabilities and equity1.14 billion950 million+19.8%
Operating cash flow61.37 million-15.18 million+504.3%
Investing cash flow-2.1 million-21.01 million+90.0%
Financing cash flow-40.63 million30.41 million−233.6%
Net change in cash18.64 million-5.78 million+422.5%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
October Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy